Vanda Presents Three Imsidolimab Data Sets for Rare Skin Disease GPP at EADV
Image
Washington – October 02, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is presenting three new data sets on its monoclonal antibody imsidolimab at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Vienna, Austria, running September 30 through October 3, 2026.
Vanda shows imsidolimab cuts neutrophil levels rapidly in GPP patients
Poster P1769 (Abstract AS-4323) reports a rapid reduction in neutrophils and the neutrophil percentage-to-albumin ratio following imsidolimab treatment in patients with generalized pustular psoriasis (GPP), a rare orphan skin condition.
Immunogenicity data on imsidolimab presented in separate poster
A second poster, P1784 (Abstract AS-2420), details the immunogenicity profile of imsidolimab in GPP patients.